Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma

Sunitinib is a standard molecular-targeted drug used as a first-line treatment for metastatic clear cell renal cell carcinoma (ccRCC); however, resistance to sunitinib has become a major problem in medical practice. Recently, bromodomain containing 4 (BRD4), a member of the bromodomain family protei...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Sakaguchi, Takashi, Yoshino, Hirofumi, Sugita, Satoshi, Miyamoto, Kazutaka, Yonemori, Masaya, Osako, Yoichi, Meguro-Horike, Makiko, Horike, Shin-Ichi, Nakagawa, Masayuki, Enokida, Hideki
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955408/
https://ncbi.nlm.nih.gov/pubmed/29796168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25190
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars